Clinical trials: Takayasu Arteritis
Takayasu's Arteritis, Giant Cell Arteritis
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of the arteries in the head, neck, upper body, and arms.
- Trial name
- NCT00556439
- Testing
- Abatacept
- Where
- 10 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Purpura, Schoenlein-Henoch, Graft Versus Host Disease
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II.
- Conditions
- Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis
- Trial name
- NCT00006055
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fairview University Medical Center
Systemic Lupus, Rheumatoid Arthritis
Yellow Fever Vaccine in Patients With Rheumatic Diseases
According to World Health Organization (WHO), since December 2016, Brazil is showing a significant increase in cases of yellow fever in humans.
- Conditions
- Systemic Lupus, Rheumatoid Arthritis, Spondyloarthritis, Inflammatory Myopathy
- Trial name
- NCT03430388
- Testing
- Yellow Fever vaccine (17D)
- Where
- Brazil
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Takayasu Arteritis, Large Vessel Vasculitis
Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
Takayasu's arteritis (TAK) is a large vessel vasculitis preferentially affecting the aorta and its main branches, leading to wall vessels thickening, fibrosis, stenosis, and occlusion.
- Trial name
- STARS (NCT07477795)
- Testing
- Secukinumab, Standard of Care (SOC)
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement 2.
- Conditions
- Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty, PAH Targeted Medication
- Trial name
- NCT05388682
- Testing
- Percutaneous transluminal pulmonary angioplasty
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Vasculitis, Systemic Vasculitis
Journey of Patients With Vasculitis From First Symptom to Diagnosis
This study seeks to understand the journey that patients eventually are diagnosed with vasculitis experience in the period prior to their formal diagnosis by a healthcare provider.
- Conditions
- Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis
- Trial name
- NCT03410290
- Testing
- Online Questionnaire
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- University of Pennsylvania
Takayasu Arteritis, Anti-Inflammatory Agents
Anti-inflammatory Treatment for Inactive Takayasu Arteritis
Currently, the traditional disease activity of Takayasu arteritis is mainly based on National Institutes of Health criteria and the inactive cases don't need anti-inflammatory treatment.
- Trial name
- ATITA (NCT03550781)
- Testing
- Prednisone, cyclophosphamide
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Takayasu's Arteritis
Exercise in Juvenile Takayasu Disease
Juvenile Takayasu disease is characterized by chronic inflammation that leads to vascular disease. Exercise may render anti-inflammatory effects and protect against cardiovascular events.
- Trial name
- NCT03494062
- Testing
- Exercise
- Where
- Brazil
- Volunteers
- 21 people
- Sponsor
- University of Sao Paulo
Takayasu's Arteritis
Determining Disease Activity Biomarkers in Individuals With Takayasu's Arteritis
Takayasu's arteritis is a rare disorder that causes swelling and damage to the large arteries in the body, such as the aorta. In order to ensure proper treatment, measuring disease activity is critical.
- Trial name
- NCT00315471
- Where
- 9 sites in United States, Canada
- Volunteers
- 224 people
- Sponsor
- University of Pennsylvania
Takayasu's Arteritis, Giant Cell Arteritis
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Background: Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse.
- Conditions
- Takayasu's Arteritis, Giant Cell Arteritis, Polyarteritis Nodosa, Relapsing Polychondritis
- Trial name
- NCT02257866
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Behcet's Disease, Churg-Strauss Syndrome
VCRC Patient Contact Registry Patient-Reported Data Validation Study
The purpose of this study is to provide validation of patient-reported data in the VCRC Patient Contact Registry by comparing patient-reported data with data provided by the physician who is the primary provider caring for the…
- Conditions
- Behcet's Disease, Churg-Strauss Syndrome, Giant Cell Arteritis, Wegener Granulomatosis
- Trial name
- NCT02190942
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- University of South Florida
Arteritis, Takayasu
The Long-term Success of Cardiovascular Surgery in Takayasu Arteritis
Takayasu Arteritis (TA) affects medium and large caliber arteries causing stenosis, occlusion or aneurysms. It has great predilection for the aortic arch, subclavian and extracranial arteries.
- Trial name
- NCT03654222
- Where
- Mexico
- Volunteers
- 66 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Systemic Vasculitis, Arteritis, Takayasu
Study of Refractory and/or Relapsing TAkayasu aRTeritis
Takayasu arteritis (TA) is a vasculitis of unknown origin, resulting in progressive thickening and stenosis of large and medium arteries (the aorta and its major branches, and the pulmonary arteries).
- Conditions
- Systemic Vasculitis, Arteritis, Takayasu, Arteritis
- Trial name
- START (NCT03543527)
- Testing
- no intervention
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Giant Cell Arteritis, Takayasu Arteritis
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Vasculitis occur when the body's immune system, rather than protecting the body, attacks blood vessels, causing injury to the vessel and the part of the body it supplies with blood.
- Conditions
- Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis
- Trial name
- BIOVAS (NCT05168475)
- Testing
- Rituximab, Infliximab, Tocilizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Aortitis, Cutaneous Vasculitis
VCRC Tissue Repository
The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies.
- Conditions
- Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis
- Trial name
- NCT02967068
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Takayasu Arteritis, Pulmonary Artery Hypertension
Pulmonary Artery Involvement in Takayasu's Arteritis
The purpose of this study is to analyze the clinical manifestations, imaging features, and prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA), and to explore the early clinical features of…
- Trial name
- NCT03189602
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking Union Medical College Hospital
Takayasu Arteritis (TAK)
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
The main objective of this study is to evaluate the efficacy of upadacitinib in combination with a corticosteroid taper regimen compared to placebo in combination with a corticosteroid taper regimen.
- Trial name
- SELECT-TAK (NCT04161898)
- Testing
- Upadacitinib, Prednisolone
- Where
- 48 sites in Argentina, Brazil and 4 more
- Volunteers
- 56 people
- Sponsor
- AbbVie
Takayasu Arteritis, Cardiovascular Diseases
Cardiovascular Risk in Patients With Takayasu Arteritis: A Nationwide Population-Based Cohort Study
This nationwide observational cohort study compares the risk of major adverse cardiovascular events (MACE) and territory-specific arterial complications between patients with incident Takayasu arteritis and matched…
- Trial name
- TAK-CV-2026 (NCT07686991)
- Where
- 2 sites in France
- Volunteers
- 8,275 people
- Sponsor
- Groupe français d'étude des Maladies Inflammatoires de loeil
Takayasu Arteritis, Tocilizumab
A Pilot Study in Severe Patients With Takayasu Arteritis.
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe.
- Conditions
- Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment
- Trial name
- NCT04300686
- Testing
- Tocilizumab, Adalimumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital